Mark K Wedel

Title: Mark K Wedel: Innovator in Antisense Oligonucleotide Therapies

Introduction

Mark K Wedel is a prominent inventor based in Temecula, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antisense oligonucleotide therapies. With a total of 4 patents, his work has the potential to impact the treatment of various medical conditions.

Latest Patents

Among his latest patents, Wedel has developed methods for administering antisense oligonucleotides that are complementary to human apolipoprotein B. These methods aim to provide long-term lowering of lipid levels in human subjects and treat conditions associated with elevated LDL-cholesterol and elevated ApoB. Another notable patent involves therapeutic antisense oligonucleotide compositions for the treatment of inflammatory bowel disease. This method focuses on the sustained amelioration and treatment of ulcerative colitis through rectal administration of a specific antisense oligonucleotide sequence. The results indicate a decrease in ulcerative colitis symptoms for over 90 days after treatment, with minimal systemic exposure and good tolerance.

Career Highlights

Throughout his career, Mark K Wedel has worked with notable companies in the biotechnology sector, including Isis Pharmaceuticals, Inc. and Genzyme Corporation. His experience in these organizations has allowed him to refine his expertise in developing innovative therapeutic solutions.

Collaborations

Wedel has collaborated with esteemed colleagues such as Philip P Miner, Jr. and Richard S Geary. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Mark K Wedel's innovative work in antisense oligonucleotide therapies showcases his commitment to advancing medical science. His contributions have the potential to significantly improve treatment options for patients with various health conditions.